CytomX Therapeutics (CTMX) Equity Average (2016 - 2025)
CytomX Therapeutics (CTMX) has disclosed Equity Average for 11 consecutive years, with $113.6 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Equity Average rose 515.7% year-over-year to $113.6 million, compared with a TTM value of $113.6 million through Sep 2025, up 515.7%, and an annual FY2024 reading of -$24.0 million, up 64.04% over the prior year.
- Equity Average was $113.6 million for Q3 2025 at CytomX Therapeutics, up from $72.5 million in the prior quarter.
- Across five years, Equity Average topped out at $113.6 million in Q3 2025 and bottomed at -$86.2 million in Q1 2023.
- Average Equity Average over 5 years is -$12.9 million, with a median of -$27.3 million recorded in 2024.
- The sharpest move saw Equity Average tumbled 654.8% in 2022, then skyrocketed 515.7% in 2025.
- Year by year, Equity Average stood at $15.0 million in 2021, then crashed by 654.8% to -$83.1 million in 2022, then surged by 40.66% to -$49.3 million in 2023, then soared by 75.77% to -$12.0 million in 2024, then skyrocketed by 1050.72% to $113.6 million in 2025.
- Business Quant data shows Equity Average for CTMX at $113.6 million in Q3 2025, $72.5 million in Q2 2025, and $12.3 million in Q1 2025.